Marwan Fakih

机构：City Of Hope National Medical Center, City of Hope · ORCID：0000-0002-6554-5488

发表论文 702 篇 · 总被引 28793 次 · h-index 73

代表论文

• Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer (2025 · Journal of Clinical Oncology · 被引 47)
• Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial (2025 · The Lancet · 被引 42)
• Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial (2025 · The Lancet · 被引 32)
• Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors (2025 · Journal for ImmunoTherapy of Cancer · 被引 14)
• Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors (2025 · European Journal of Cancer · 被引 13)
• Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial (2025 · The Lancet Oncology · 被引 12)